Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
New gene therapy findings from Paul-Ehrlich-Institute published
June 3rd, 2009
Investigators publish new data in the report 'Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity.' "We pseudotyped HIV-1 vectors with cytoplasmic tail-truncated envelope glycoproteins of a wild-type (WT) measles virus (MV)," investigators in Langen, Germany report. "The particles entered the lymphatic cells exclusively through the signaling lymphocyte activation molecule (SLAM, CD150), whereas particles pseudotyped with the MV vaccine strain glycoproteins also recognized the ubiquitous membrane cofactor protein (CD46) as receptor and had less specific cell entry. MV(WT)-HIV vectors reached titers of...
Source: Vaccine Weekly (2009-06-03)
|
